[1]
|
Chapuy, B., Stewart, C., Dunford, A.J., et al. (2018) Molecular Subtypes of Diffuse Large B Cell Lymphoma Are Asso-ciated with Distinct Pathogenic Mechanisms and Outcomes. Nature Medicine, 24, 679-690.
|
[2]
|
Sun, L., Zhang, H. and Gao, P. (2021) Metabolic Reprogramming and Epigenetic Modifications on the Path to Cancer. Protein & Cell, 13, 877-919. https://doi.org/10.1007/s13238-021-00846-7
|
[3]
|
Esteller, M. (2008) Epigenetics in Cancer. The New England Journal of Medicine, 358, 1148-1159.
https://doi.org/10.1056/NEJMra072067
|
[4]
|
Lee, J.E. and Kim, M.Y. (2021) Cancer Epigenetics: Past, Present and Future. Seminars in Cancer Biology, 83, 4-14.
https://doi.org/10.1016/j.semcancer.2021.03.025
|
[5]
|
Frazzi, R., Zanetti, E., Pistoni, M., et al. (2017) Methylation Changes of SIRT1, KLF4, DAPK1 and SPG20 in B-Lymphocytes Derived from Follicular and Diffuse Large B-Cell Lymphoma. Leukemia Research, 57, 89-96.
https://doi.org/10.1016/j.leukres.2017.02.012
|
[6]
|
Frazzi, R., Cusenza, V.Y., Pistoni, M., et al. (2022) KLF4, DAPK1 and SPG20 Promoter Methylation Is Not Affected by DNMT1 Silencing and Hypomethylating Drugs in Lym-phoma Cells. Oncology Reports, 47, Article No. 10.
https://doi.org/10.3892/or.2021.8221
|
[7]
|
Özdemir, İ., Pınarlı, F.G., Pınarlı, F.A., et al. (2018) Epigenetic Silenc-ing of the Tumor Suppressor Genes SPI1, PRDX2, KLF4, DLEC1, and DAPK1 in Childhood and Adolescent Lym-phomas. Pediatric Hematology and Oncology, 35, 131-144. https://doi.org/10.1080/08880018.2018.1467986
|
[8]
|
Cao, B., Guo, X., Huang, L., et al. (2021) Methylation Si-lencing CDH23 Is a Poor Prognostic Marker in Diffuse Large B-Cell Lymphoma. Aging, 13, 17768-17788. https://doi.org/10.18632/aging.203268
|
[9]
|
Giesen, D., Hooge, M.N.L., Nijland, M., et al. (2022) 89Zr-PET Imag-ing to Predict Tumor Uptake of 177Lu-NNV003 Anti-CD37 Radioimmunotherapy in Mouse Models of B Cell Lympho-ma. Scientific Reports, 12, Article No. 6286.
https://doi.org/10.1038/s41598-022-10139-6
|
[10]
|
Elfrink, S., Ter Beest, M., Janssen, L., et al. (2022) IRF8 Is a Transcriptional Activator of CD37 Expression in Diffuse Large B-Cell Lymphoma. Blood Advances, 6, 2254-2266. https://doi.org/10.1182/bloodadvances.2021004366
|
[11]
|
Wedge, E., Hansen, J.W., Garde, C., et al. (2017) Global Hypomethylation Is an Independent Prognostic Factor in Diffuse Large B Cell Lymphoma. American Journal of Hema-tology, 92, 689-694. https://doi.org/10.1002/ajh.24751
|
[12]
|
Sun, X.J., Chen, Z. and Chen, S.J. (2019) Mutations in DNA Methyltransferases and Demethylases. In: Boffetta, P. and Hainaut, P., Eds., Encyclopedia of Cancer, Academic Press, Cambridge, 528-537.
|
[13]
|
Duy, C., Béguelin, W. and Melnick, A. (2020) Epigenetic Mechanisms in Leukemias and Lymphomas. Cold Spring Harbor Perspectives in Medicine, 10, a034959. https://doi.org/10.1101/cshperspect.a034959
|
[14]
|
Dominguez, P.M., Ghamlouch, H., Rosikiewicz, W., et al. (2018) TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-Cell Lym-phomagenesis. Cancer Discovery, 8, 1632-1653.
https://doi.org/10.1158/2159-8290.CD-18-0657
|
[15]
|
Jiao, J., Lv, Z., Zhang, P., et al. (2020) AID Assists DNMT1 to Attenuate BCL6 Expression through DNA Methylation in Diffuse Large B-Cell Lymphoma Cell Lines. Neoplasia, 22, 142-153. https://doi.org/10.1016/j.neo.2020.01.002
|
[16]
|
Nieto, Y., Valdez, B.C., Thall, P.F., et al. (2016) Double Epigenetic Modulation of High-Dose Chemotherapy with Azacitidine and vorinostat for Patients with Refractory or Poor-Risk Relapsed Lymphoma. Cancer, 122, 2680-2688.
https://doi.org/10.1002/cncr.30100
|
[17]
|
Deng, Y., Chen, X., Huang, C., et al. (2019) EZH2/Bcl-2 Coexpression Predicts Worse Survival in Diffuse Large B-Cell Lymphomas and Demonstrates Poor Efficacy to Rituximab in Localized Lesions. Journal of Cancer, 10, 2006-2017. https://doi.org/10.7150/jca.29807
|
[18]
|
Zhou, Y., Wang, X., An, Y.H., et al. (2020) Mechanism of Sorafenib and Decitabine Inducing Apoptosis of Diffuse Large B-Cell Lymphoma Cells. Journal of Experimental Hematology, 28, 146-152.
|
[19]
|
Kwon, M., Park, K., Hyun, K., et al. (2020) H2B Ubiquityla-tion Enhances H3K4 Methylation Activities of Human KMT2 Family Complexes. Nucleic Acids Research, 48, 5442-5456. https://doi.org/10.1093/nar/gkaa317
|
[20]
|
Ortega-Molina, A., Boss, I.W., Canela, A., et al. (2015) The Histone Lysine Methyltransferase KMT2D Sustains a Gene Expression Program That Represses B Cell Lymphoma De-velopment. Nature Medicine, 21, 1199-1208.
https://doi.org/10.1038/nm.3943
|
[21]
|
Persky, D.O., Li, H., Rimsza, L.M., et al. (2018) A Phase I/II Trial of Vori-nostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806. American Journal of Hematology, 93, 486-493. https://doi.org/10.1002/ajh.25010
|
[22]
|
Patrizia, M., Brea, E.J., et al. (2018) Panobinostat Acts Synergistically with Ibrutinib in Diffuse Large B Cell Lymphoma Cells with MyD88 L265 Mutations. JCI Insight, 3, e125568. https://doi.org/10.1172/jci.insight.125568
|
[23]
|
Islam, P., Rizzieri, D., Lin, C., et al. (2021) Phase II Study of Sin-gle-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Cancer Investigation, 39, 871-879.
https://doi.org/10.1080/07357907.2021.1983584
|
[24]
|
Zhang, H., Chi, F., Qin, K., et al. (2021) Chidamide Induces Apoptosis in DLBCL Cells by Suppressing the HDACs/STAT3/Bcl2 Pathway. Molecular Medicine Reports, 23, Article No. 308.
https://doi.org/10.3892/mmr.2021.11947
|
[25]
|
Wang, L., Qin, W., Huo, Y.J., et al. (2020) Advances in Targeted Therapy for Malignant Lymphoma. Signal Transduction and Targeted Therapy, 5, Article No. 15. https://doi.org/10.1038/s41392-020-0113-2
|
[26]
|
Gulati, N., Béguelin, W. and Giulino-Roth, L. (2018) Enhancer of Zeste Homolog 2 (EZH2) Inhibitors. Leukemia & Lymphoma, 59, 1574-1585. https://doi.org/10.1080/10428194.2018.1430795
|
[27]
|
Italiano, A., Soria, J.C., Toulmonde, M., et al. (2018) Taze-metostat, an EZH2 Inhibitor, in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Advanced Solid Tumours: A First-in-Human, Open-Label, Phase 1 Study. The Lancet Oncology, 19, 649-659. https://doi.org/10.1016/S1470-2045(18)30145-1
|
[28]
|
Alderuccio, J.P. and Sharman, J.P. (2022) ABCs of ADCs in Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood Reviews, 56, Article ID: 100967. https://doi.org/10.1016/j.blre.2022.100967
|
[29]
|
Yap, T.A., Winter, J.N., Giulino-Roth, L., et al. (2019) Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hemato-logic and Solid Tumors. Clinical Cancer Research, 25, 7331-7339. https://doi.org/10.1158/1078-0432.CCR-18-4121
|
[30]
|
Mei, H., Wu, H., Yang, J., et al. (2023) Discovery of IHMT-337 as a Potent Irreversible EZH2 Inhibitor Targeting CDK4 Transcription for Malignancies. Signal Transduction and Targeted Therapy, 8, Article No. 18.
https://doi.org/10.1038/s41392-022-01240-3
|